REVA Medical Pioneers Live Demonstration of MOTIV® Technology at VIVA26

Successful Live Case Demonstration of MOTIV® at VIVA26

REVA Medical, a leader in bioresorbable vascular technology, has successfully demonstrated its innovative MOTIV® stent technology in a live case during the Vascular InterVentional Advances (VIVA) 2026 conference, held in Las Vegas, Nevada. The event showcased significant advancements in treating critical limb ischemia, highlighting the effectiveness of the MOTIV® stent in real-time medical application.

Overview of the Live Case Procedure

The demonstration featured Dr. Andrej Schmidt from University Hospital Leipzig, who performed a live revascularization procedure on a 72-year-old female patient suffering from chronic limb-threatening ischemia (CLTI) and classified in Rutherford category 5. The patient had a non-healing ulcer and was at high risk of limb loss. Dr. Schmidt utilized two MOTIV® stents, one measuring 4.0 mm × 48 mm and the other 3.5 mm × 24 mm, to successfully restore blood flow in a peripheral artery beneath the knee. The procedure concluded with an excellent angiographic result, demonstrating the stent's effectiveness in promoting vascular healing.

Highlighting Clinical Trial Results

In addition to the live demonstration, Dr. Ehrin Armstrong from HCA HealthOne Swedish Medical Center presented late-breaking results from the pivotal MOTIV BTK clinical trial. This randomized, prospective, multicenter study involved 292 patients with CLTI, comparing the MOTIV® stents against standard balloon angioplasty treatment. The trial's focus was to evaluate the efficacy of the MOTIV® stent, especially in patients classified under Rutherford categories 4 and 5, which represent significant disease stages.

The findings revealed favorable outcomes for the MOTIV® stents, particularly in primary patency and limb salvage rates. At the six-month mark, the outcomes showed that 87.2% of Rutherford category 4 patients achieved the composite endpoint of limb salvage and primary patency, compared to 76.3% for those treated with balloon angioplasty. Likewise, for Rutherford 5 patients, 77.0% reached the endpoint with the MOTIV® stent compared to just 55.8% for angioplasty.

By the twelve-month follow-up, the MOTIV® stent continued to outperform balloon angioplasty, with remarkable results across both patient categories: 76.7% for Rutherford 4 and 65.7% for Rutherford 5 patients compared to lower percentages with PTA.

Implications of the Results

Jeffrey Anderson, CEO of REVA Medical, expressed that these results and live demonstrations underline the potential of the MOTIV® technology in addressing complex vascular conditions. CLTI is a severe form of peripheral artery disease leading to severe pain, non-healing wounds, and potentially amputation. The bioresorbable nature of the MOTIV® stent aims to provide necessary structural support during the healing period and then dissolve, avoiding the need for permanent implants.

The company emphasizes that the device is still under investigation and is thus restricted for research use only under federal law in the United States. With their successful demonstration at VIVA26, REVA Medical reaffirms its commitment to advancing treatment options for patients suffering from limb-threatening vascular diseases.

Conclusion

The successful live demonstration of the MOTIV® stent at VIVA26 not only showcases technological innovation in the medical field but also opens doors to improved treatment protocols for patients with critical limb ischemia. As REVA Medical continues to develop and refine their bioresorbable technologies, the future holds promise for enhanced patient care and outcomes.

For further updates and information, visit REVA Medical’s LinkedIn page.